Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
46 Cards in this Set
- Front
- Back
Hodgkin's
age |
younger than NHL
|
|
Hodgkin's
incidence |
increased slightly
male and female same |
|
hodgkin's
orgin |
unifocal
|
|
hodgkin's
pattern of spread |
predictable
|
|
hodgkin's
rold of surgery |
diagnosis
|
|
hodgkin's
role of RT |
Primary tx for early-stage or combined with chemo for advanced
|
|
hodgkin's
chemo agents |
MOPP
ABVD ChIVPP |
|
hodgkin's
survival |
85% overall 5 year
81% overall 10 year |
|
non-hodgkin's
incidence |
highest in US
higher in males |
|
non-hodgkin's
age |
over 50
|
|
non-hodgkin's
origin |
focal
|
|
non-hodgkin's
pattern of spread |
unpredictable
|
|
non-hodgkin's
role of surgery |
diagnosis
|
|
non-hodgkin's
role of RT |
Role of RT has decreased as chemo regimens have become more effective.
|
|
non-hodgkin's
cheo agents |
single alkalating agents
CVP CHOP |
|
non-hodgkin's
survival |
65% overall 5 year
54% overall 10 year |
|
non-hodgkin's
2 RT portals areas blocked |
1. Involved-field irradiation
2. Extended-field irradiation Block: lungs, spinal cord, larynx, heart, humoral and femoral heads, kidneys, gonads, and iliac crest bone marrow. |
|
hodgkin's
2 RT portals areas blocked |
1. Total nodal irradiation: (Inverted Y)
2. Subtotal nodal irradiation Block: lungs, spinal cord, larynx, heart, humoral and femoral heads, kidneys, gonads, and iliac crest bone marrow. |
|
hodgkin's
chemo role |
Treats all sites of disease at the outset and reduces bulky disease to facilitate subsequent irradiation
|
|
non-hodgkin's
chemo role |
Mainstay of tx as NHLs present as systemic disease
|
|
hodgkin's
RT dose |
36-44Gy in 1.5-1.8Gy fractions
|
|
non-hodgkin's
RT dose |
30-40Gy in 1.5-2.0Gy fractions
|
|
Stage I
|
single node region or lymphoid structure
|
|
Stage IE
|
single extralymphatic organ/site
|
|
Stage II
|
2 or more node regions
same side of diaphragm |
|
Stage IIE
|
single node region + localized single extralymphatic orgin/site
|
|
Stage III
|
node regions
both sides of diaphragm |
|
Stage IIIE
|
+/- involvement of localized, single extralymphatic organ/site
|
|
Stage IIIS
|
+/- involvement of spleen
|
|
Stage IIIE+S
|
+/- involvement of both
|
|
Stage IV
|
diffuse involvement of extralymphatic organ/site +/- node regions
|
|
multiple myeloma
neoplastic profliferation cells |
malignant plasma cell turmor
|
|
multiple myeloma
race of highest incidence |
non-white
|
|
multiple myeloma
symptoms |
bone pain
|
|
multiple myeloma
3 roles of RT |
1. Palliation or pain relief
2. Prevention of pathologic fractures in weight-bearing bones 3. Spinal cord compression |
|
multiple myeloma
role of chemo |
palliation of pain
|
|
multiple myeloma
chemo agents |
Alkylating agents (Melphalan) combined with prednisone
VAD VBCMP |
|
5 acute
|
nausea
vomiting fatigue erythema change in bowels |
|
5 chronic
|
sterility
BM suppression Pneumonitis Pericarditis Hypothyroidism |
|
mantle nodes
|
Mediastinal, hilar, cervical, axillary, and supraclavicular and infraclavicular nodes.
|
|
mini mantle
|
Cervical, axillary, and supraclavicular and infraclavicular nodes.
|
|
extended mantle
|
Mantle including para-aortic nodes to L3 or L4 and splenic pedicle.
|
|
spade
|
Para-aortic, splenic pedicle (or spleen), and common iliac nodes.
|
|
Inverted Y
|
Spleen or splenic pedicle, para-aortic, iliac, and inguinal and femoral nodes.
|
|
Total nodal irradiation (TNI)
|
mantle, para-aortic/splenic pedicle (or spleen), and pelvis or mantle and inverted Y.
|
|
Subtotal nodal irradiation (STNI)
|
Mantle and para-aortic/splenic pedicle (or spleen).
|